5 news items
Autolus Therapeutics Reports First Quarter 2024 Financial Results and Business Updates
AUTL
17 May 24
; [Link]In February 2024, Autolus announced the publication of a paper in Nature Communications
Autolus Therapeutics announces acceptance of Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (B-ALL)
AUTL
2 Apr 24
A. NoonanS.A. Noonan Communications+1-917-513-5303
Breaking Down Autolus Therapeutics: 4 Analysts Share Their Views
AUTL
18 Mar 24
attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks
Autolus Therapeutics Reports Full Year 2023 Financial Results and Business Updates
AUTL
14 Mar 24
announced the publication of a paper in Nature Communications entitled: ‘Structure-Guided Engineering of Immunotherapies Targeting TRBC1 and TRBC2 in T
Autolus Therapeutics receives Medicines and Healthcare products Regulatory Agency (MHRA) certification for Nucleus commercial manufacturing site
AUTL
12 Mar 24
@autolus.com Susan A. NoonanS.A. Noonan Communications+1-917-513-5303
- Prev
- 1
- Next